MX9302725A - Metodos para regular la formacion de la proteina beta-amiloide. - Google Patents
Metodos para regular la formacion de la proteina beta-amiloide.Info
- Publication number
- MX9302725A MX9302725A MX9302725A MX9302725A MX9302725A MX 9302725 A MX9302725 A MX 9302725A MX 9302725 A MX9302725 A MX 9302725A MX 9302725 A MX9302725 A MX 9302725A MX 9302725 A MX9302725 A MX 9302725A
- Authority
- MX
- Mexico
- Prior art keywords
- amyloid protein
- beta
- methods
- formation
- regulate
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 102000013455 Amyloid beta-Peptides Human genes 0.000 title abstract 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 title abstract 2
- 230000015572 biosynthetic process Effects 0.000 title 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 abstract 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 102000014303 Amyloid beta-Protein Precursor Human genes 0.000 abstract 1
- 108010079054 Amyloid beta-Protein Precursor Proteins 0.000 abstract 1
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 abstract 1
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 abstract 1
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 abstract 1
- 102000009091 Amyloidogenic Proteins Human genes 0.000 abstract 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 abstract 1
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 239000004365 Protease Substances 0.000 abstract 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 1
- 102000012479 Serine Proteases Human genes 0.000 abstract 1
- 108010022999 Serine Proteases Proteins 0.000 abstract 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 abstract 1
- 239000003696 aspartic proteinase inhibitor Substances 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 230000014616 translation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6478—Aspartic endopeptidases (3.4.23)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/81—Protease inhibitors
- G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- G01N2333/8142—Aspartate protease (E.C. 3.4.23) inhibitors, e.g. HIV protease inhibitors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96472—Aspartic endopeptidases (3.4.23)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Cell Biology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US88091492A | 1992-05-11 | 1992-05-11 | |
| US99566092A | 1992-12-16 | 1992-12-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX9302725A true MX9302725A (es) | 1994-08-31 |
Family
ID=27128594
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX9302725A MX9302725A (es) | 1992-05-11 | 1993-05-10 | Metodos para regular la formacion de la proteina beta-amiloide. |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP0569777A2 (OSRAM) |
| JP (1) | JPH08268911A (OSRAM) |
| KR (1) | KR930023469A (OSRAM) |
| AU (1) | AU679675B2 (OSRAM) |
| CA (1) | CA2095888A1 (OSRAM) |
| IL (1) | IL105632A0 (OSRAM) |
| MX (1) | MX9302725A (OSRAM) |
| NZ (1) | NZ247575A (OSRAM) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ181493A3 (en) * | 1992-09-10 | 1994-03-16 | Lilly Co Eli | The use of rhodanine derivative for the preparation of a pharmaceutical composition reducing level of sugar in blood and for treating alzheimer's disease |
| NZ264143A (en) * | 1993-08-09 | 1996-11-26 | Lilly Co Eli | Use of an aspartyl protease inhibitor to inhibit beta-amyloid peptide production |
| US6251928B1 (en) * | 1994-03-16 | 2001-06-26 | Eli Lilly And Company | Treatment of alzheimer's disease employing inhibitors of cathepsin D |
| US5804560A (en) * | 1995-01-06 | 1998-09-08 | Sibia Neurosciences, Inc. | Peptide and peptide analog protease inhibitors |
| US6017887A (en) * | 1995-01-06 | 2000-01-25 | Sibia Neurosciences, Inc. | Peptide, peptide analog and amino acid analog protease inhibitors |
| GB9608657D0 (en) * | 1996-04-26 | 1996-07-03 | Smithkline Beecham Plc | Novel treatment |
| DE19641180A1 (de) * | 1996-09-24 | 1998-03-26 | Schering Ag | Verfahren zur Darstellung von APP-Sekretase Modulation und deren Verwendung als Mittel zur Behandlung der Alzheimer'schen Erkrankung |
| WO1998015828A1 (en) * | 1996-10-07 | 1998-04-16 | Scios Inc. | Method to identify direct inhibitors of the beta-amyloid forming enzyme gamma-secretase |
| EP1084240A1 (fr) * | 1998-06-05 | 2001-03-21 | Aventis Pharma S.A. | Polypeptides possedant une activite de type beta-secretase |
| FR2779444A1 (fr) * | 1998-06-05 | 1999-12-10 | Rhone Poulenc Rorer Sa | Polypeptides possedant une activite de type beta-secretase et capables de cliver le precurseur naturel du peptide beta-amyloide (app) |
| US6472421B1 (en) | 1998-11-13 | 2002-10-29 | Nymox Corporation | Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an HMG CoA reductase inhibitor |
| ES2312348T3 (es) * | 1999-06-16 | 2009-03-01 | Boston Biomedical Research Institute | Control inmunologico de niveles de beta-amiloide in vivo. |
| JP2013158281A (ja) * | 2012-02-03 | 2013-08-19 | Shionogi & Co Ltd | 新規ｂａｃｅ１活性測定方法 |
| CN119044471A (zh) * | 2024-08-30 | 2024-11-29 | 南京质谱医学科技有限公司 | Tau蛋白抗体-CNBr复合物及其制备方法、检测方法、试剂盒和应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUT62312A (en) * | 1990-03-05 | 1993-04-28 | Cephalon Inc | Process for producing chymotrypsin-like proteases and their inhibitors |
| US5292652A (en) * | 1990-10-05 | 1994-03-08 | Athena Neurosciences, Inc. | Amyloidin protease and uses thereof |
| CA2086165A1 (en) * | 1992-04-09 | 1993-10-10 | Paul P. Tamburini | Diagnostic assay for alzheimer's disease based on the proteolysis of alzheimer's precursor protein |
| EP0694076A1 (en) * | 1992-12-16 | 1996-01-31 | Bayer Corporation | Cathepsin d is an amyloidogenic protease in alzheimer's disease |
-
1993
- 1993-04-22 AU AU37110/93A patent/AU679675B2/en not_active Ceased
- 1993-04-28 EP EP93106884A patent/EP0569777A2/en not_active Withdrawn
- 1993-05-07 NZ NZ247575A patent/NZ247575A/en unknown
- 1993-05-07 IL IL105632A patent/IL105632A0/xx unknown
- 1993-05-10 MX MX9302725A patent/MX9302725A/es unknown
- 1993-05-10 CA CA002095888A patent/CA2095888A1/en not_active Abandoned
- 1993-05-10 KR KR1019930007963A patent/KR930023469A/ko not_active Withdrawn
- 1993-05-11 JP JP5132535A patent/JPH08268911A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU3711093A (en) | 1993-11-18 |
| JPH08268911A (ja) | 1996-10-15 |
| AU679675B2 (en) | 1997-07-10 |
| CA2095888A1 (en) | 1993-11-12 |
| EP0569777A3 (OSRAM) | 1993-12-01 |
| IL105632A0 (en) | 1993-09-22 |
| KR930023469A (ko) | 1993-12-18 |
| EP0569777A2 (en) | 1993-11-18 |
| NZ247575A (en) | 1996-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR013441A1 (es) | Un compuesto de imidazoquinoxalina, metodo para el tratamiento de un padecimiento o desorden asociado con la proteina tirosinaquinasa, lascomposiciones farmaceuticas que las contienen y metodos para preparar dichos compuestos y sus intermediarios | |
| YU37696A (sh) | Postupak optičkog prečišćavanja jedinjenja | |
| ECSP055738A (es) | PROCESO ENANTIOSELECTIVO PARA LA PREPARACIÓN DE AMBOS ENANTIÓMEROS DE 10,11-DIHIDRO-10-HIDROXI-5H-DIBENZ-[b,f]-AZEPIN-5-CARBOXAMIDA Y SUS NUEVAS FORMAS DE CRISTAL | |
| ATE310087T1 (de) | Plasma-kallikrein inhibitoren vom kunitz-typ | |
| ES2191102T3 (es) | Heterociclos de peptidilo utiles en el tratamiento de las afecciones relacionadas con la trombina. | |
| ATE307592T1 (de) | Epiallopregnanolon zur behandlung von krankheiten des cns | |
| TR200101307T2 (tr) | Antranilik asit amidler ve ilaç olarak kullanılmaları. | |
| EA200201183A1 (ru) | Новые полициклические соединения и их применение | |
| ES2054747T3 (es) | Nuevos antidepresivos. | |
| PT695758E (pt) | Amidas e esteres de pentapeptidos inibidores de cancro humano | |
| DE69530392D1 (de) | Inhibitoren der leukozytenadhäsion | |
| ES2165990T3 (es) | Thip para el tratamiento de trastornos del sueño. | |
| ES2053588T3 (es) | Inhibidores de las serina-proteasas. | |
| BR9815469A (pt) | Inibidores de protease | |
| MX9303082A (es) | Proteasa y componentes relacionados con el dna. | |
| DE69931957D1 (de) | Verwendung von sibutramin zur behandlung von von organischen störungen verursachten zns-erkrankungen | |
| EE200400005A (et) | Tablett, mis sisaldab vähemalt kahte eristatavat segmenti ning selle kasutamine | |
| ATE226254T1 (de) | Reagenz zur behandlung von arthritischen zustaenden | |
| DK0714394T3 (da) | Antipsykotisk fremgangsmåde | |
| DK0506836T3 (da) | BCRF1 proteiner som inhibitorer for interferon-gamma | |
| AR009819A1 (es) | Inhibidores de la proteasa proteinicos estabilizados y sus variantes | |
| MX9804459A (es) | Procedimiento para el diagnostico y terapia de epitelioma. | |
| PT1124556E (pt) | Utilizacao de (r)-tofisopam opticamente puro para tratamento e prevencao de perturbacoes da ansiedade e sua composicao | |
| SV1998000023A (es) | Arilsulfonamidas y analogos ref. lea 32316-sv | |
| HUP9802531A2 (hu) | Eljárás haematopoeticus stem sejtek mobilizálására |